Harmony Biosciences HRMY 深 沪
已收盘 10-16 16:00:00 美东时间
37.95
-0.320
-0.84%
华盛通- 最 高39.00
- 今 开38.47
- 成交量 89.23万股
- 最 低 37.85
- 昨 收 38.27
- 总市值 22.10亿
- 52周最高 43.49
- 市盈率 静 14.00
- 换手率 1.53%
- 52周最低 25.902
- 委 比 75.00%
- 总股本 5823.64万
- 历史最高 62.085
- 量 比 0.92
- 振 幅 3.00%
- 历史最低 18.6112
- 每 手 1
- 风险率 4.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target
Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.
10-12 21:27
Harmony Biosciences appoints Peter Anastasiou as CEO
Harmony Biosciences (HRMY) announced Monday Peter Anastasiou has been appointed president, chief executive officer, and member of the Board of Directors, effective January 1, 2027. The firm highlighte...
10-12 19:40
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Harmony Biosciences announced that Peter Anastasiou, former board member and Sr. EVP/COO, will become President and CEO effective January 1, 2027. Jeffrey M. Dayno, current CEO, will retire at year-end after nine years with the company. Harmony reaffirms 2026 WAKIX net revenue guidance of $1.0B-$1.04B, expects BP-205 MAD study data in Q4 2026, and remains focused on strategic priorities including CNS pipeline advancement and WAKIX exclusivity pro...
10-12 11:00
Undervalued healthcare stocks with attractive valuation grades
Healthcare stocks continue to attract investor attention as managed care providers, pharmaceutical companies, biotechnology firms and healthcare services businesses navigate changing demand and indust...
09-16 01:15
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60
Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.
08-26 19:50
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Harmony Biosciences Says New Data Supports Neurology Pipeline
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) shares closed higher by around 8% on Tuesday following the company’s announcement of record revenue for the second quarter of 2026. The neurological disease-focused pharma company reported second quarter earnings of $1.28 per share, beating the consen...
08-05 18:56
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
